Hong Kong
· Delayed Price · Currency is HKD Keymed Biosciences Statistics
Total Valuation
HKG:2162 has a market cap or net worth of HKD 12.40 billion. The enterprise value is 10.91 billion.
| Market Cap | 12.40B |
| Enterprise Value | 10.91B |
Important Dates
The last earnings date was Friday, March 28, 2025.
| Earnings Date | Mar 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
HKG:2162 has 275.60 million shares outstanding. The number of shares has increased by 0.22% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 275.60M |
| Shares Change (YoY) | +0.22% |
| Shares Change (QoQ) | +0.30% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 25.24% |
| Float | 184.35M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 27.22 |
| PB Ratio | 4.71 |
| P/TBV Ratio | 4.73 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -19.90 |
| EV / Sales | 23.95 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.30, with a Debt / Equity ratio of 0.30.
| Current Ratio | 3.30 |
| Quick Ratio | 2.97 |
| Debt / Equity | 0.30 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -33.92 |
Financial Efficiency
Return on equity (ROE) is -18.85% and return on invested capital (ROIC) is -11.69%.
| Return on Equity (ROE) | -18.85% |
| Return on Assets (ROA) | -10.23% |
| Return on Invested Capital (ROIC) | -11.69% |
| Return on Capital Employed (ROCE) | -20.74% |
| Revenue Per Employee | 362,160 |
| Profits Per Employee | -435,855 |
| Employee Count | 1,258 |
| Asset Turnover | 0.11 |
| Inventory Turnover | 0.14 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +39.32% in the last 52 weeks. The beta is -0.03, so HKG:2162's price volatility has been lower than the market average.
| Beta (5Y) | -0.03 |
| 52-Week Price Change | +39.32% |
| 50-Day Moving Average | 39.06 |
| 200-Day Moving Average | 36.58 |
| Relative Strength Index (RSI) | 58.61 |
| Average Volume (20 Days) | 2,945,142 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, HKG:2162 had revenue of HKD 455.60 million and -548.31 million in losses. Loss per share was -2.09.
| Revenue | 455.60M |
| Gross Profit | 442.61M |
| Operating Income | -666.26M |
| Pretax Income | -541.29M |
| Net Income | -548.31M |
| EBITDA | -611.32M |
| EBIT | -666.26M |
| Loss Per Share | -2.09 |
Balance Sheet
The company has 2.29 billion in cash and 801.58 million in debt, giving a net cash position of 1.49 billion or 5.41 per share.
| Cash & Cash Equivalents | 2.29B |
| Total Debt | 801.58M |
| Net Cash | 1.49B |
| Net Cash Per Share | 5.41 |
| Equity (Book Value) | 2.63B |
| Book Value Per Share | 10.04 |
| Working Capital | 1.83B |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 97.15%, with operating and profit margins of -146.24% and -120.35%.
| Gross Margin | 97.15% |
| Operating Margin | -146.24% |
| Pretax Margin | -118.81% |
| Profit Margin | -120.35% |
| EBITDA Margin | -134.18% |
| EBIT Margin | -146.24% |
| FCF Margin | n/a |
Dividends & Yields
HKG:2162 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.22% |
| Shareholder Yield | -0.22% |
| Earnings Yield | -4.42% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |